Crispr and CRISPR-associated (Cas) proteins form an adaptive immune system that protects bacteria and archaea from viruses by cleaving the viral DNA. This ability to target and edit genes with high specificity has revolutionized genome editing. Some key advantages of CRISPR/Cas9 technology include ease of use, flexibility, specificity and affordability. Crispr/Cas9 technology has tremendous potential applications in disease modeling, developing gene and cell therapies, genetic engineering, and targeted therapy.
The Global Crispr And Cas Gene Market is estimated to be valued at US$ 1.78 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period from 2024 to 2031.
Key Takeaways
Key players in the Crispr And Cas Gene Market Size include Rescroft Ltd., USSC Group, Inc., Magna International, Inc., Rojac Urethane Limited, GRAMMER AG, TransCal, Freedman Seating Co., Delimajaya Group, Franz Kiel GmbH, iFoam Ltd., Compin-Fainsa, FlexoFoam Pvt. Ltd., FISA Srl, FENIX Group, LLC, and Kustom Seating Unlimited, Inc. and Others. These players are focusing on new product launches and expansion of their global footprint to tap immense opportunities in the market. For instance, in 2023 Rescroft Ltd launched its new CRISPR gene editing research kits and tools to provide a complete workflow solution for genome engineering research.
The global crispr and cas gene market is expected to grow significantly over the forecast period due to rising demand for therapeutics using genome editing technologies. Crispr/Cas9 technology offers promising therapeutic applications in treating genetic disorders like sickle cell disease, cystic fibrosis, and cancer. Several clinical trials are currently underway to evaluate the safety and efficacy of CRISPR gene therapies.
Get more insights on - Crispr And Cas Gene Market
